JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

Search

Cencora Inc

Fermé

SecteurSoins de santé

307.65 -1.16

Résumé

Variation du prix de l'action

24h

Actuel

Min

298.7

Max

311.26

Chiffres clés

By Trading Economics

Revenu

906M

566M

Ventes

2.2B

86B

P/E

Moyenne du Secteur

37.19

67.147

BPA

4.08

Rendement du dividende

0.73

Marge bénéficiaire

0.659

Employés

47,000

EBITDA

858M

1B

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+29.04% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.73%

2.36%

Prochains Résultats

6 mai 2026

Date du Prochain Dividende

1 juin 2026

Date du Prochain Détachement de Dividende

15 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-10B

60B

Ouverture précédente

308.81

Clôture précédente

307.65

Sentiment de l'Actualité

By Acuity

7%

93%

6 / 348 Classement par Healthcare

Cencora Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

29 avr. 2026, 23:53 UTC

Résultats

Naver Posts Weaker First-Quarter Earnings

29 avr. 2026, 23:41 UTC

Actions en Tendance

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29 avr. 2026, 23:55 UTC

Résultats

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29 avr. 2026, 23:54 UTC

Résultats

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29 avr. 2026, 23:52 UTC

Résultats

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29 avr. 2026, 23:51 UTC

Résultats

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29 avr. 2026, 23:51 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29 avr. 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29 avr. 2026, 23:24 UTC

Résultats

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29 avr. 2026, 23:24 UTC

Résultats

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29 avr. 2026, 23:24 UTC

Résultats

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29 avr. 2026, 23:24 UTC

Résultats

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29 avr. 2026, 23:22 UTC

Résultats

China Longyuan 1Q Net CNY1.70B, Down 14%

29 avr. 2026, 23:22 UTC

Résultats

China Longyuan: Power Generation Down 2.9% as of End-March

29 avr. 2026, 23:20 UTC

Résultats

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29 avr. 2026, 23:20 UTC

Résultats

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29 avr. 2026, 23:19 UTC

Résultats

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29 avr. 2026, 23:19 UTC

Résultats

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29 avr. 2026, 23:19 UTC

Résultats

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29 avr. 2026, 23:19 UTC

Résultats

China Vanke 1Q Loss Narrows>000002.SZ

29 avr. 2026, 23:18 UTC

Résultats

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29 avr. 2026, 23:17 UTC

Résultats

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29 avr. 2026, 23:15 UTC

Résultats

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29 avr. 2026, 23:15 UTC

Résultats

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29 avr. 2026, 23:13 UTC

Résultats

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29 avr. 2026, 23:12 UTC

Résultats

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29 avr. 2026, 23:11 UTC

Résultats

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29 avr. 2026, 23:11 UTC

Résultats

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29 avr. 2026, 23:04 UTC

Résultats

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29 avr. 2026, 23:04 UTC

Résultats

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Comparaison

Variation de prix

Cencora Inc prévision

Objectif de Prix

By TipRanks

29.04% hausse

Prévisions sur 12 Mois

Moyen 401.86 USD  29.04%

Haut 429 USD

Bas 360 USD

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

8 ratings

6

Achat

2

Maintien

0

Vente

Sentiment

By Acuity

6 / 348Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Moyen

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Cencora Inc

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
help-icon Live chat